Trial profile Mann JF et al. Lancet 2008;372:547-53.

Slides:

Advertisements

Similar presentations

A Comparison of Early Versus Late Initiation of Renal Replacement Therapy in Critically III Patients with Acute Kidney Injury: A Systematic Review and.

Advertisements

Montalescot G, et al. Lancet 2009;373: Trial profile Montalescot G, et al. Lancet 2009;373:

Trial profile Fox K et al. Lancet 2008;372:

The ONTARGET Trial Reference The ONTARGET investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:15.

Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.

Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.

The effect of heart rate reduction with ivabradine on renal function in patients with chronic heart failure: an analysis from SHIFT Systolic Heart failure.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Renal damage occurs in 1 out of 4 hypertensives Adapted from Leoncini et al. J Hypertens. 2008;26:

Background There are 12 different types of medications to lower blood sugar levels in patients with type 2 diabetes. It is widely agreed upon that metformin.

ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)

Slide Source Kaplan-Meier Curve of Time to Primary End Point Proportion of Events (%) Pioglitazone Placebo PROactive investigators.

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.

Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]

6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.

Diabetes and the Kidney Richard Kingston Department of Renal Medicine Kent and Canterbury Hospital.

The FRET Study Source: Inoue T, Ikeda H, Nakamura T, et al. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin.

Date of download: 6/23/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Sickle Cell Trait With Chronic Kidney.

Clinical Outcomes with Newer Antihyperglycemic Agents

Clinical Outcomes with Newer Antihyperglycemic Agents

From: Effects of Intensive Systolic Blood Pressure Control on Kidney and Cardiovascular Outcomes in Persons Without Kidney DiseaseA Secondary Analysis.

RIFLE criteria for acute kidney injury

Chronic Kidney Disease in Diabetes

Melody Sherwood, Peter A McCullough The Lancet Global Health

Fig. 1. Distribution of eGFR according to baseline SCr

Early Evolution and Correlates of Urine Albumin Excretion in Patients Presenting With Acutely Decompensated Heart FailureClinical Perspective by Satoshi.

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Summary of Design Aim: Effect of Ramipril (up to 10mg/d) or Vit E (400 IU/d) vs its placebo on CV death, M I or stroke (primary) Design: Randomized double.

Systolic Heart failure treatment with the If inhibitor ivabradine Trial The effect of heart rate reduction with ivabradine on renal function in patients.

Recent studies of ACE inhibition in renal disease

Management of hypertension in patients with chronic kidney disease

Trial profile John A Dormandy et al. Lancet 2005;366:

Biomarkers in kidney fibrosis: are they useful?

Trial analysis results comparing ACE inhibitors/ARBs with other antihypertensive drugs on renal disease progression End point Relative risk (95% CI) p.

Update on Diabetic Nephropathy: Core Curriculum 2018

A: Kaplan-Meier estimate of time to first LLA

Corrections to "Estimating the glomerular filtration rate from serum creatinine is better than from cystatin C for evaluating risk factors associated.

Melody Sherwood, Peter A McCullough The Lancet Global Health

End point Fenoldopam, n (%) Dopamine, n (%) p

Nat. Rev. Nephrol. doi: /nrneph

Your Kidneys May Outlive You

Erratum American Journal of Kidney Diseases

Volume 4, Pages (October 2018)

Enrollment and Outcomes

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Long-term study of mycophenolate mofetil treatment in IgA nephropathy

Payan Schober et al. Am J Nephrol 2017;45: (DOI: / )

Volume 85, Issue 6, Pages (June 2014)

Trial profile GISSI-HF investigators. Lancet 2008; Aug 29 [Epub ahead of print]

Volume 76, Issue 10, Pages (November 2009)

Volume 83, Issue 4, Pages (April 2013)

Volume 81, Issue 6, Pages (March 2012)

Update on Diabetic Nephropathy: Core Curriculum 2018

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

The Lancet Diabetes & Endocrinology

Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

(G) Body mass index (BMI) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (G) Body mass index (BMI) values.

Volume 83, Issue 3, Pages (March 2013)

Comparison of Baseline Characteristics by Primary End Point

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Two-year changes in albumin-to-creatinine ratio across microalbuminuria at baseline. Two-year changes in albumin-to-creatinine ratio across microalbuminuria.

Among three residual kidney function (RKF) indices, only residual urine volume (UV) indicated an independent prognostic value in patients with UV≥0.1 or.

Kaplan-Meier survival (renal event-free) curves during follow-up by tertiles of plasma copeptin. Kaplan-Meier survival (renal event-free) curves during.

Dot plots comparing changes in renal function at pretreatment and after the first and last cycles in both hydration groups. Dot plots comparing changes.

Figure 1. (A) Composite renal outcome, (B) worsening kidney function, and (C) incident albuminuria by fasting glucose ... Figure 1. (A) Composite renal.

Fistula and Survival Outcomes after Fistula Creation among Predialysis Chronic Kidney Disease Stage 5 Patients Miyamoto et al. Am J Nephrol 2017;45:

Diagnostic criteria for AKI

Changes of major clinical and biochemical characteristics at baseline and during follow-up in different groups. Changes of major clinical and biochemical.

Presentation transcript:

Trial profile Mann JF et al. Lancet 2008;372:547-53

Decrease in estimated glomerular filtration rate (eGFR) during the trial, from baseline to study end Mann JF et al. Lancet 2008;372:547-53

Estimated glomerular filtration rate at baseline and changes of eGFR Mann JF et al. Lancet 2008;372:547-53

Incidence of primary and secondary renal outcomes and of its components Mann JF et al. Lancet 2008;372:547-53

Kaplan-Meier curves for (A) primary renal outcome (dialysis, doubling of serum creatinine, and death), (B) secondary renal outcome (dialysis and doubling of serum creatinine), and (C) dialysis T=telmisartan R=ramipril Mann JF et al. Lancet 2008;372:547-53

Relative risk for primary renal outcome in subgroups (A) Comparison of ramipril and telmisartan The interaction term tests whether there is an interaction of the subgroup with the two treatment modalities Mann JF et al. Lancet 2008;372:547-53

Relative risk for primary renal outcome in subgroups (B) Comparison of ramipril and telmisartan plus ramipril The interaction term tests whether there is an interaction of the subgroup with the two treatment modalities Mann JF et al. Lancet 2008;372:547-53

Changes in log urine albumin to creatinine ratio Mann JF et al. Lancet 2008;372:547-53